News about "Biocon"

Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili

Biocon has published pivotal clinical data supporting the effectiveness of Yesafili, its Food and Drug Administration (FDA)-approved interchangeable aflibercept biosimilar, demonstrating comparable safety, efficacy, and immunogenicity.

Biocon | 09/07/2026 | By News Bureau |  106

Biocon Expands Diabetes Care in Malaysia as Duopharma Wins Insulin Tenders

Biocon strengthens diabetes care in Malaysia as Duopharma Biotech secures insulin tenders worth over MYR 225 million for human insulin, insulin glargine, and insulin aspart.

Biocon | 26/06/2026 | By News Bureau

Biocon Launches Bosaya and Aukelso Denosumab Biosimilars in US

Biocon launches Bosaya and Aukelso denosumab biosimilars in the US following FDA approval with interchangeable status, expanding treatment options for osteoporosis and bone metastasis patients.

Biocon | 08/04/2026 | By News Bureau |  119

Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon

Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.

Biocon | 08/12/2025 | By Dineshwori |  133

Biocon Clarifies Media Reports on Possible Biocon Biologics Merger

Biocon has issued a clarification regarding recent media reports suggesting that the company is considering a potential merger of its unlisted subsidiary, Biocon Biologics Ltd. (BBL), along with IPO and share swap options.

Biocon | 14/11/2025 | By Dineshwori |  388

Biocon Posts Robust Q2FY26 Results as Biosimilars and Generics Drive Double-Digit Growth

Biocon reported a robust financial performance for the second quarter of FY26, with total revenue rising 21 percent year-on-year (YoY) to INR 4,389 crore, compared to INR 3,623 crore in Q2 FY25.

Biocon | 12/11/2025 | By Dineshwori |  451

Biocon's Cranbury Facility in US Passes FDA Inspection, Supports Expansion Plans

Biocon’s inspection concluded with a single observation, which the company will address within the stipulated timeframe, and it is not expected to impact ongoing business operations

Biocon | 15/10/2025 | By Dineshwori |  272

Enzene, Aurobindo and Biocon Boost US Manufacturing with Major New Jersey Expansions

This month, three leading Indian firms — Enzene Biosciences, Aurobindo Pharma, and Biocon — have inaugurated major facilities in New Jersey, underscoring a growing trend of onshore investment by Indian pharma companies.

Biocon | 18/09/2025 | By Dineshwori |  497

Biocon Opens First US Manufacturing Facility in New Jersey

The Cranbury facility will help Biocon diversify its manufacturing base, strengthen its supply chain
and accelerate the expansion of its global footprint.

Biocon | 11/09/2025 | By Dineshwori |  219

Biocon Biologics Secures FDA Approval for Kirsty

Biocon Biologics has announced that it has received FDA approval for KIRSTY (Insulin Aspart-xjhz), making it the first and only interchangeable biosimilar to NovoLog in the US, marking a major milestone in expanding affordable insulin options.

Biocon | 16/07/2025 | By Mrinmoy Dey |  319